Agile Therapeutics Inc (NASDAQ:AGRX) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 844,663 shares, a drop of 24.9% from the February 15th total of 1,125,414 shares. Based on an average daily trading volume, of 362,532 shares, the short-interest ratio is presently 2.3 days. Approximately 3.6% of the shares of the stock are short sold.

Several hedge funds have recently added to or reduced their stakes in AGRX. Fosun International Ltd acquired a new stake in shares of Agile Therapeutics in the third quarter valued at approximately $180,000. Renaissance Technologies LLC grew its position in shares of Agile Therapeutics by 54.3% in the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 430,907 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 226,255 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Agile Therapeutics by 24.0% in the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of Agile Therapeutics by 15.7% in the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the last quarter. Institutional investors and hedge funds own 42.15% of the company’s stock.

A number of brokerages have issued reports on AGRX. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 11th. Maxim Group reiterated a “buy” rating and issued a $3.00 price target on shares of Agile Therapeutics in a research report on Monday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Agile Therapeutics in a research report on Friday, January 11th.

AGRX stock opened at $1.61 on Friday. The company has a market capitalization of $57.41 million, a PE ratio of -2.78 and a beta of 0.36. Agile Therapeutics has a 12 month low of $0.23 and a 12 month high of $3.24.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. Sell-side analysts predict that Agile Therapeutics will post -0.65 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.thecerbatgem.com/2019/03/16/short-interest-in-agile-therapeutics-inc-agrx-decreases-by-24-9.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Article: What are trading strategies for the 52-week high/low?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.